Progress in systemic therapy of advanced hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 22, Issue 29, 2016, Pages 6582-6594

  Gong, Xin Lei ^a   Qin, Shu Kui ^a  

^a Bayi Hospital   (China)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Molecular targeted therapy; Progress; Systemic therapy

Indexed keywords

AXITINIB; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CAPECITABINE; CAPMATINIB; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; FORETINIB; GALUNISERTIB; GEMCITABINE; LENVATINIB; LINIFANIB; NIVOLUMAB; OXALIPLATIN; PAZOPANIB; PEGARGIMINASE; PEXASTIMOGENE DEVACIREPVEC; PLACEBO; RAMUCIRUMAB; REFAMETINIB; REGORAFENIB; SORAFENIB; SUNITINIB; TEPOTINIB; TICILIMUMAB; TIVANTINIB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PLATINUM COMPLEX; TRANSFORMING GROWTH FACTOR BETA;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CHEMOEMBOLIZATION; CHRONIC HEPATITIS C; COLORECTAL CANCER; DIARRHEA; DISTANT METASTASIS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LOSS OF APPETITE; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RADIOFREQUENCY ABLATION; RASH; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VOMITING; WEAKNESS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; IMMUNOTHERAPY; LIVER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; LEUCOVORIN; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; ORGANOPLATINUM COMPOUNDS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84982790520     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i29.6582     Document Type: Review

References (70)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108 [PMID: 25651787 DOI: 10.3322/caac.21262]
2. Chen WQ, Zheng RS, Zhang SW, Zeng HM, Zuo TT, Jia MM, Xia CF, Zhou XN, He j. Report of Cancer Incidence and Mortality in China, 2012. Zhongguo Zhongliu 2016; 25: 1-8 [DOI: 10.11735/j.issn.1004-0242.2016.01.A001]
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115-132 [PMID: 26808342 DOI: 10.3322/caac.21338]
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30 [PMID: 26742998 DOI: 10.3322/caac.21332]
5. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013; 31: 3501-3508 [PMID: 23980077 DOI: 10.1200/JCO.2012.44.5643]
6. Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, Fan J, Liang L, Zhang Y, Wu G, Rau KM, Yang TS, Jian Z, Liang H, Sun Y. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist 2014; 19: 1169-1178 [PMID: 25223462 DOI: 10.1634/theoncologist.2014-0190]
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
8. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045]
9. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31: 3517-3524 [PMID: 23980084 DOI: 10.1200/JCO.2012.48.4410]
10. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 31: 3509-3516 [PMID: 23980090 DOI: 10.1200/JCO.2012.47.3009]
11. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-4075 [PMID: 24081937 DOI: 10.1200/JCO.2012.45.8372]
12. Zhu AX, Ryoo B, Yen C, Kudo M, Poon R, Pastorelli D, Blanc J, Chung H, Baron A, Pfiffer T, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada P, Yang L, Schwartz J, Park J. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Results from the randomized phase III REACH study. Annals of Oncology 2014; 25 Suppl 5: v1-v41
13. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014; 312: 57-67 [PMID: 25058218 DOI: 10.1001/jama.2014.7189]
14. Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015; 33: 172-179 [PMID: 25488963 DOI: 10.1200/JCO.2013.54.3298]
15. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK. SEARCH: a phase III, randomized, doubleblind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015; 33: 559-566 [PMID: 25547503 DOI: 10.1200/JCO.2013.53.7746]
16. Song TJ, Fong Y, Cho SJ, Gönen M, Hezel M, Tuorto S, Choi SY, Kim YC, Suh SO, Koo BH, Chae YS, Jarnagin WR, Klimstra DS. Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis. J Surg Oncol 2012; 106: 84-88 [PMID: 22234941 DOI: 10.1002/jso.23036]
17. Zhu AX, Galle PR, Kudo M, Finn RS, Yang L, Abada P, Chang SC, Llovet JM. A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alphafetoprotein following first-line sorafenib (REACH-2). J Clin Oncol 2016; 34 suppl 4: abstract TPS478
18. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 2658-2667 [PMID: 22421192 DOI: 10.1158/1078-0432.CCR-11-1900]
19. Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 2013; 49: 3412-3419 [PMID: 23809766 DOI: 10.1016/j.ejca.2013.05.028]
20. Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K, Tamura T. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer 2014; 14: 530 [PMID: 25047123 DOI: 10.1186/1471-2407-14-530]
21. Ikeda M, Okusaka T, Mitsunaga S, Ueno H, Tamai T, Suzuki T, Hayato S, Kadowaki T, Okita K, Kumada H. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2016; 22: 1385-1394 [PMID: 26500236 DOI: 10.1158/1078-0432.CCR-15-1354]
22. Finn RS, Cheng AL, Ikeda K, Kudo M, Tamai T, Dutcus CE, Younger S, Han KH, Qin S, Raymond E.A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. J Clin Oncol 2014; 32 Suppl 5: abstract TPS 4153
23. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol 2016; 34: 1448-1454 [PMID: 26884585 DOI: 10.1200/JCO.2015.63.5995]
24. Qin SK. Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial. J Clin Oncol 2014; 32 Suppl 5: abstract 4019
25. Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, Rau KM, Poon RT, Yeo W, Park JW, Tay MH, Hsieh WS, Kappeler C, Rajagopalan P, Krissel H, Jeffers M, Yen CJ, Tak WY. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin Cancer Res 2014; 20: 5976-5985 [PMID: 25294897 DOI: 10.1158/1078-0432. CCR-13-3445]
26. Fornaro L, Vivaldi C, Caparello C, Sacco R, Rotella V, Musettini G, Luchi S, Baldini EE, Falcone A, Masi G. Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. Future Oncol 2014; 10: 285-304 [PMID: 24490614 DOI: 10.2217/fon.13.181]
27. You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011; 54: 879-889 [PMID: 21618573 DOI: 10.1002/hep.24450]
28. Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, Engelman JA, Fujita N. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013; 73: 3087-3096 [PMID: 23598276 DOI: 10.1158/0008-5472.CAN-12-3256]
29. Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B, Lamar M, Savage RE, Bruix J. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer 2013; 108: 21-24 [PMID: 23287988 DOI: 10.1038/bjc.2012.556]
30. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63 [PMID: 23182627 DOI: 10.1016/S1470-2045(12)70490-4]
31. Rimassa L, Abbadessa G, Personeni N, Porta C, Borbath I, Daniele B, Van Laethem J, Van Vlieberghe H, Trojan J, de Toni E, Peck-Radosavljevic M, Finn RS, Raoul J, He AR, Lamar M, Wang Y, Von Roemeling RW, Schwartz BE, Bruix J, Santoro A. Tumor and plasma biomarker analysis from the randomized controlled phase II trial of tivantinib in second-line hepatocellular carcinoma (HCC). J Clin Oncol 2016; 34 Suppl 4: abstract 197
32. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639-3646 [PMID: 24002501 DOI: 10.1200/JCO.2012.48.4659]
33. Verslype C, Cohn AL, Kelley RK, Yang T, Su W, Ramies DA, Lee Y, Shen X, Van Cutsem E. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a Phase II randomized discontinuation trial (RDT). J Clin Oncol 2012; 30 Suppl 15: abstract 4007
34. Yau T, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Lencioni R, Camp AC, Cox DS, Kallender H, Ottesen LH, Poon RTP. A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2012; 30 Suppl 15: abstract 4108
35. Qin S, Cheng AL, Lim HY, Xu L, Bladt F, Johne A, Li C, Zheng H, Massimini G. A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET) advanced hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function. J Clin Oncol 2014; 32 Suppl 5: abstract TPS4151
36. Bang YJ, Su WC, Nam DH, Lim WT, Bauer TM, Brana I, Poon RTP, Hong DS, Lin CC, Peng B, Zhang Y, Zhao S, Kumar A, Akimov M, Ma B. Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. J Clin Oncol 2014; 32 Suppl 5: abstract 2520
37. Qin SK, Sukeepaisarnjaroen W, Chan SL, Choo SP, Han GH, Sriuranpong V, Pan HM, Yau T, Ren ZG, Xu JM, Peng B, Saji T, Sun YJ, Huang A, Manenti L, Tanwandee T. A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2016; In press
38. Liu L, Zeng W, Wortinger MA, Yan SB, Cornwell P, Peek VL, Stephens JR, Tetreault JW, Xia J, Manro JR, Credille KM, Ballard DW, Brown-Augsburger P, Wacheck V, Chow CK, Huang L, Wang Y, Denning I, Davies J, Tang Y, Vaillancourt P, Lu J. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res 2014; 20: 6059-6070 [PMID: 25231402 DOI: 10.1158/1078-0432.CCR-14-0543]
39. O'Neil BH, Bendell JC, Modiano MR, Machiels JPH, Versola MJ, Hodge JP, Sawarna K, Tse N. Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results. J Clin Oncol 2013; Suppl 4: abstract 94
40. Harding JJ, Bendell JC, Fuchs CS, Wang X, Wacheck V, Zhu AX. Emibetuzumab plus ramucirumab: Simultaneous targeting of MET and VEGFR-2 in patients with advanced hepatocellular cancer in a phase 1b/2 study. J Clin Oncol 2016; 34 Suppl 4: abstract 300
41. Faivre SJ, Santoro A, Kelley RK, Merle P, Gane E, Douillard JY, Waldschmidt D, Mulcahy MF, Costentin C, Minguez B, Papappicco P, Gueorguieva I, Cleverly A, Desaiah D, Lahn MM, Ameryckx S, Benhadji KA, Raymond E, Giannelli G. A phase 2 study of a novel transforming growth factorbeta (TGF-{beta} 1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2014; 32 Suppl 3: abstract LBA173
42. Yau T, Chen PJ, Chan P, Curtis CM, Murphy PS, Suttle AB, Gauvin J, Hodge JP, Dar MM, Poon RT. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res 2011; 17: 6914-6923 [PMID: 21831954 DOI: 10.1158/1078-0432. CCR-11-0793]
43. McNamara MG, Le LW, Horgan AM, Aspinall A, Burak KW, Dhani N, Chen E, Sinaei M, Lo G, Kim TK, Rogalla P, Bathe OF, Knox JJ. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer 2015; 121: 1620-1627 [PMID: 25565269 DOI: 10.1002/cncr.29227]
44. Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol 2015; 26: 2457-2463 [PMID: 26386123 DOI: 10.1093/annonc/mdv388]
45. Zaanan A, Williet N, Hebbar M, Dabakuyo TS, Fartoux L, Mansourbakht T, Dubreuil O, Rosmorduc O, Cattan S, Bonnetain F, Boige V, Taïeb J. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol 2013; 58: 81-88 [PMID: 22989572 DOI: 10.1016/j.jhep.2012.09.006]
46. Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, Boige V. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest New Drugs 2014; 32: 1028-1035 [PMID: 24748335 DOI: 10.1007/s10637-014-0100-y]
47. Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. Clin Oncol (R Coll Radiol) 2014; 26: 488-496 [PMID: 24856442 DOI: 10.1016/j.clon.2014.04.031]
48. Liu L, Zheng YH, Han L, Qin SK. Efficacy and safety of oxaliplatinbased chemotherapy for advanced primary hepatic carcinoma: A systemic review and meta analysis of prospective studies. Linchuang Zhongliuxue Zazhi 2015; 20: 769-779
49. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-2160 [PMID: 21081728 DOI: 10.1001/jama.2010.1672]
50. Abou-Alfa GK, Niedzwieski D, Knox JJ, Kaubisch A, Posey J, Tan BR, Kavan P, Goel R, Murray JJ, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, Siegel A, Balletti J, Harding JJ, Schwartz LH, Goldberg RM, Bertagnolli MM, Venook AP. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J Clin Oncol 2016; 34 Suppl 4: abstract 192
51. Williet N, Dubreuil O, Boussaha T, Trouilloud I, Landi B, Housset M, Botti M, Rougier P, Belghiti J, Taieb J. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. World J Gastroenterol 2011; 17: 2255-2258 [PMID: 21633538 DOI: 10.3748/wjg.v17.i17.2255]
52. Assenat E, Boige V, Thézenas S, Pageaux GP, Peron JM, Becouarn Y, Dahan L, Merle P, Blanc JF, Bouche O, Ramdani M, Mazard T, Bleuse JP, Ychou M. Sorafenib (S) alone vs S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial). J Clin Oncol 2013; 31 Suppl 4: abstract 4028
53. Yau T, Cheung FY, Lee F, Choo SP, Wong H, Toh HC, Leung AK, Chan P, Yau TK, Wong J, Tang YF, Lau SMJ, Cheung TT, Fan ST, Poon RTP. A multi-center phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study. J Clin Oncol 2013; 31. Suppl 4: abstract 4117
54. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723 [PMID: 20525992 DOI: 10.1056/NEJMoa1003466]
55. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550 [PMID: 26712084 DOI: 10.1016/S0140-6736(15)01281-7]
56. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373: 1627-1639 [PMID: 26412456 DOI: 10.1056/NEJMoa1507643]
57. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373: 1803-1813 [PMID: 26406148 DOI: 10.1056/NEJMoa1510665]
58. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013; 13: 5 [PMID: 23390376]
59. Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy 2013; 5: 215-229 [PMID: 23444951 DOI: 10.2217/imt.13.9]
60. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013; 59: 81-88 [PMID: 23466307 DOI: 10.1016/j.jhep.2013.02.022]
61. Duffy AG, Makarova-Rusher OV, Kerkar SP, Kleiner DE, Fioravanti S, Walker M, Carey S, Figg WD, Steinberg SM, Anderson V, Abi-Jaoudeh N, Levi E, Wood BJ, Greten TF. A pilot study of tremelimumab-a monoclonal antibody against CTLA-4-in combination with either transcatheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2015; 33 Suppl 15: abstract 4081
62. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20: 5064-5074 [PMID: 24714771 DOI: 10.1158/1078-0432. CCR-13-3271]
63. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 2015; 11: 1307-1326 [PMID: 25798726 DOI: 10.2217/fon.15.52]
64. El-Khoueiry AB, Melero I, Crocenzi TS, Welling III TH, Yau T, Yeo W, Chopra A, Grosso JF, Lang L, Anderson J, dela Cruz C, Sangro B. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015; 33 Suppl 15: abstract LBA101
65. Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012; 20: 749-758 [PMID: 22186794 DOI: 10.1038/mt.2011.276]
66. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19: 329-336 [PMID: 23396206 DOI: 10.1038/nm.3089]
67. Breitbach CJ, Moon A, Burke J, Hwang TH, Kirn DH. A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma. Methods Mol Biol 2015; 1317: 343-357 [PMID: 26072416 DOI: 10.1007/978-1-4939-2727-2-19]
68. Abou-Alfa GK, Galle P, Chao Y, Brown K, Heo J, Borad M, Luca A, Limacher JM, Agathon D, Lusky M, Pelusio A, Breitbach C, Burke J, Qin SK. PHOCUS: A Phase 3 Randomized, Open-Label Study Comparing the Oncolytic Immunotherapy Pexa Vec Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy. J Clin Oncol 2016; In press
69. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, Curley SA. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004; 22: 1815-1822 [PMID: 15143074 DOI: 10.1200/JCO.2004.11.120]
70. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang-Peng J, Chen PJ, Chen LT. A randomised phase II study of pegylated arginine deiminase (ADIPEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010; 103: 954-960 [PMID: 20808309 DOI: 10.1038/sj.bjc.6605856]